Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSP 576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)

Next Previous
Trial Profile

CSP 576 - VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aripiprazole (Primary) ; Bupropion (Primary) ; Antidepressants
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms VAST-D

Most Recent Events

  • 23 Jun 2020 Results (N=717), a secondary analysis assessing the impact of concurrent Posttraumatic Stress Disorder (PTSD) on outcomes of Antipsychotic augmentation for Major Depressive Disorder, published in the Journal of Clinical Psychiatry
  • 01 Dec 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
  • 10 Sep 2012 Planned End Date changed from 1 Sep 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top